Remibrutinib
Remibrutinib, sold under the brand name Rhapsido, is a medication used for the treatment of chronic spontaneous urticaria.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Remibrutinib, sold under the brand name Rhapsido, is a medication used for the treatment of chronic spontaneous urticaria. Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton's tyrosine kinase. It is taken by mouth.
Remibrutinib was approved for medical use in the United States in September 2025, and in the European Union in April 2026. The US Food and Drug Administration considers it to be a first-in-class medication.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378607938 under CC BY-SA 4.0; modifications have been made.